Partnership with THREAD

THREAD, an industry leading DCT platform with comprehensive eCOA, and IMA Clinical Research are partnering as a preferred THREAD site partner. Through our dedicated research sites and satellite site network, THREAD enables hybrid and fully decentralized clinical trial (DCT) studies, bringing broad geographic access to diverse patient populations across the United States.

THREAD is a DCT platform with services that deliver global scalability and rapid flexibility for virtual trials—from study design to study closeout. The platform provides configurable data collection methods with options for reminders, workflows and data visuals. In partnership with IMA Clinical Research, THREAD will support and enhance IMA Clinical Research’s site network capabilities in decentralized clinical trials.

At IMA Clinical Research, our mission is to advance the development of new medical treatments through a flexible clinical trial network that reaches people everywhere. In addition to our traditional, site-based trials, we offer hybrid and fully decentralized, or virtual, clinical trials to extend our reach. Coupled with centralized contracting and rigorous regulatory adherence, IMA Clinical Research is uniquely positioned to accelerate startup and deliver high-quality studies across our network.

IMAgine the possibilities of a partnership between IMA Clinical Research and THREAD. Follow us on LinkedIn.

About IMA Clinical Research:

IMA Clinical Research, a division of The IMA Group, is a physician-founded network of integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. IMA Clinical Research offers a flexible delivery model for site-based, hybrid and fully decentralized trials through its network of dedicated research clinics, a nationwide array of 100 satellite sites and a rapidly growing database of over 300,000 patients. We provide centralized processes for contracting, regulatory, training and patient recruitment, ensuring rapid startup, efficient enrollment and high-quality delivery across our network. For more information, visit or